Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis

Pain

Volumn 155, Issue 12, 2014, Pages 2461-2470

  Seretny, Marta ^a   Currie, Gillian L ^b   Sena, Emily S ^b   Ramnarine, Sabrina ^a   Grant, Robin ^a   Macleod, Malcolm R ^b   Colvin, Leslie A ^a   Fallon, Marie ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Chemotherapy induced peripheral; Meta analysis; Neuropathy (CIPN); Prevalence; Risk factors; Systematic review

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CISPLATIN; OXALIPLATIN; PACLITAXEL; THALIDOMIDE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; DRUG INDUCED DISEASE; FOLLOW UP; GENETIC RISK; HUMAN; INCIDENCE; META ANALYSIS; NEUROPATHIC PAIN; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; ADVERSE DRUG REACTION; BIBLIOGRAPHIC DATABASE; COMPLICATION; DRUG THERAPY; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE; STATISTICS AND NUMERICAL DATA;

DATABASES, BIBLIOGRAPHIC; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE OF TESTS;

EID: 84922699672     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2014.09.020     Document Type: Review

References (67)

1. Albers JW, Chaudhry V, Cavaletti G, Donehower CR. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2011;16: CD005228.
2. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T, for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94.
3. Altman DG, Vergouwe Y, Royston P, Moons KGM. Prognosis and prognostic research: validating a prognostic model. BMJ 2009;338:b605.
4. Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzis P, Assimakopoulos K, Kalofonos HP, Chroni E. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol 2007;46:1131-7.
5. Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Gourzis P, Assimakopoulos K, Kalofonos HP, Chroni E. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 2006;14:223-9.
6. Argyriou AA, Polychronopoulos P, Koutras A, Xiros N, Petsas T, Argyriou K, Kalofonos HP, Chroni E. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care 2007;16:231-7.
7. Argyriou AA, Velasco R, Briani C, Cavaletti G, Bruna J, Alberti P, Cacciavillani M, Lonardi S, Santos C, Cortinovis D, Cazzaniga M, Kalofonos HP. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 2012;23:3116-22.
8. ® 2009;144:245-52.
9. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012;18:5099-109.
10. Boland EG, Selvarajah D, Hunter M, Ezaydi Y, Tesfaye S, Ahmedzai SH, Snowden JA, Wilkinson ID. Central pain processing in chronic chemotherapy-induced peripheral neuropathy: a functional magnetic resonance imaging study. PLoS One 2014;9:5.
11. Booth A. PROSPERO: International register of systematic reviews, Available at: http://www.crd.york.ac.uk/PROSPERO; 2013 [Accessed August 29, 2013].
12. Cancer Research UK. Cancer incidence and survival rates, Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/Allcancerscom-bined/; 2013 [Accessed November 26, 2013].
13. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002;20:3478-83.
14. Cascinu S, Cordella L, Delferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric-cancer-a randomized double-blind placebo-controlled trial. J Clin Oncol 1995;13:26-32.
15. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 2011;12:1151-61.
16. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, CI-Peri Nom S Group. The Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization Study: from consensus to the first validity and reliability findings. Ann Oncol 2013;24:454-62.
17. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 2010;6:657-66.
18. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy: research report. J Peripher Nerv Syst 2008;13:275-82.
19. Colvin LA, Dougherty PM. Peripheral neuropathic pain: signs, symptoms, mechanisms, and causes: are they linked? Br J Anaesth 2014. Sep. 24. pii: aeu323. [Epub ahead of print].
20. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009;32:1-32.
21. Dimopoulos MA, Mateos M-V, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine D-L, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 2011;86:23-31.
22. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315:629-34.
23. Fallon MT. Neuropathic pain in cancer. Br J Anaesth 2013;111:105-11.
24. Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS, Weisberg SR, Williams L, Diasio RB, Perez EA, Karp D, Reich SD, McCarroll K, Hoff JV. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 1995;13:490-6.
25. Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, Hashemzade S, Asghari Jafarabadi M, Montazeri V, Keshavarz SA, Darabi M. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer 2012;12:355.
26. Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010;116:2322-31.
27. Gobran NS. Role of calcium and magnesium infusion in prevention of oxaliplatin neurotoxicity. A phase III trial. Chinese-German J Clin Oncol 2013;12:232-6.
28. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology 2012;14:45-54.
29. Guyatt GH, Sinclair J, Cook DJ, Glasziou P. Users' guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. JAMA 1999;281:1836-43.
30. ® 2002;98:195-203.
31. Hershman DL, Lacchetti C, Dworkin RH, Smith EML, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014;32:1941-67.
32. Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. IntJ Clin Oncol 2010;15:82-7.
33. Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, Lokhorst HM, Goldschmidt H, Davies FE, Durie BGM, Van Ness B, Child JA, Sonneveld P, Morgan GJ. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 2011;29:797-804.
34. Kawakami K, Tunoda T, Takiguchi T, Shibata K, Ohtani T, Kizu J, Nishio M, Horai T, Hama T, Taguchi K. Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer. Oncol Res 2012;20:179-85.
35. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized controlled trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-12.
36. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005;32:51-60.
37. Lema MJ, Foley KM, Hausheer FH. Types and epidemiology of cancer-related neuropathic pain: the intersection of cancer pain and neuropathic pain. Oncologist 2010;15:3-8.
38. Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, Yang MH, Chen PM, Lin KP, Chiou TJ. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer 2006;14:484-7.
39. Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anti-Cancer Drugs 2009;20:396-402.
40. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 2014;40:872-82.
41. Mitchell P, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, Clarke S, White S. Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC). J Clin Oncol 2005;23. 266S-266S.
42. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev 2006;51:240-64.
43. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
44. National Cancer Institute. Cancer Survival Statistics, Available at: http://seer.cancer.gov/statfacts/html/all.html; 2013 [Accessed December 12, 2013].
45. Pace A, Giannarelli D, Galiè E, Savarese A, Carpano S, Della Giulia M, Pozzi A, Silvani A, Gaviani P, Scaioli V, Jandolo B, Bove L, Cognetti F. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 2010;74:762-6.
46. Pace A, Nistico C, Cuppone F, Bria E, Galie E, Graziano G, Natoli G, Sperduti I, Jandolo B, Calabretta F, Tomao S, Terzoli E. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer 2007;7:550-4.
47. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, Biroccio A, Leonetti C, Jandolo B, Cognetti F, Bove L. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003;21:927-31.
48. Pachman DR, Barton DL, Watson JC, Loprinzi CL Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 2011;90:377-87.
49. Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA-A Cancer J Clinicians 2013;63:419-37.
50. Park SB, Krishnan AV, Lin CSY, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008;15:3081-94.
51. Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012;2012:913848.
52. Planting AST, Catimel G, De Mulder PHM, De Graeff A, Hoppener F, Verweij J, Oster W, Vermorken JB, for the EORTC Head and Neck Cooperative Group. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann Oncol 1999;10:693-700.
53. Plasmati R, Pastorelli F, Cavo M, Petracci E, Zamagni E, Tosi P, Cangini D, Tacchetti P, Salvi F, Bartolomei I, Michelucci R, Tassinari GA. Neuropathy in multiple myeloma treated with thalidomide-a prospective study. Neurology 2007;69:573-81.
54. Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, Gross HM, Renno SI, Nashawaty M, Loprinzi CL. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy-a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2008;112:2802-8.
55. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy-a phase 3 randomized, double-blind, placebo-controlled, crossover trial (NOOC3). Cancer 2007;110:2110-8.
56. Sikandar S, Patel R, Patel S, Sikander S, Bennett DL, Dickenson AH. Genes, molecules and patients-emerging topics to guide clinical pain research. Eur J Pharmacol 2013;716:188-202.
57. Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, for the Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309:1359-67.
58. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JPT. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Br Med J 2011;343:d4002.
59. Turner EL, Sweeting MJ, Lindfield RJ, De Angelis D. Incidence estimation using a single cross-sectional age-specific prevalence survey with differential mortality. Stat Med 2013;33:422-35.
60. Vanderhoop RG, Vecht CJ, Vanderburg MEL, Elderson A, Boogerd W, Heimans JJ, Vries EP, Vanhouwelingen JC, Jennekens FGI, Gispen WH, Neijt JP. Prevention of cisplatin neurotoxicity with an ACTH (4-9) analog in patients with ovarian-cancer. N Engl J Med 1990;322:89-94.
61. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, for the STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
62. Von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012;73:638-52.
63. Von Schlippe M, Harland SJ. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer 2001;85:823-6.
64. ® 2007;133:47-63.
65. Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, Kim JW, Lee SY, Park SH. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 2012;118:2828-36.
66. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959-64.
67. Zedan AH, Vilholm OJ. Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires. Basic Clin Pharmacol Toxicol 2014;115:193-200.